Imatinib in Patients with Aggressive Fibromatosis and Pigmented Villonodular Synovitis: A Systematic Review

Document Type : Original Article

Authors

1 Firrozgar Hospital, Iran University of Medical Sciences, Tehran, Iran

2 Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran.

3 Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran

4 Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, IR Iran

10.30483/rijm.2021.254210.1057

Abstract

Introduction: We undertook a systematic review of the literature to determine the
efficacy and safety of Imatinib in the restriction of activity and effective treatment of
patients with aggressive fibromatosis (AF) and pigmented villonodular synovitis (PVNS)
and their recurrence.
Method: We searched studies in the PubMed and Cochrane collaborative library at all
levels from 2010 to April 2019. Two independent reviewers evaluated the articles
according to the predefined criteria and extracted the related data. Primary outcomes
associated with tumor size shrinkage, relapse and overall survival along with secondary
outcomes such as pain, quality of life, and side effects were investigated.
Results: 112 studies were evaluated out of which only 6 studies that covered original
studies and case reports were entered into this systematic review. A total of 79subjects
had participated in these six studies with an age range of 22 to 41 years old. In five
studies, participants had a primary tumor and in one research they reported relapse. The
recommended dose was 400 mg/day, which was usually continued for 4 to 12 months.
The tumor size shrinkage and low side effects of drugs have been reported.
Conclusion: According to the results, no systemic treatment for PVNS and AF has been
approved so far, but many studies have demonstrated the efficacy of Imatinib in the
treatment of these diseases. However, further studies are required for optimal treatment
and combined therapies.

Keywords


  1. Blay JY, El Sayadi H, Thiesse P, garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villon-odular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19(4): 821-822. doi: 10.1093/annonc/mdn033.
  2. gu HF, Zhang SJ, Zhao C, Chen Y, Bi Q. Acomparison ofopen and arthroscopic surgery for treatment of diffuse pigmentedvillonodular synovitis of the knee. Knee Surg Sports TraumatolArthrosc 2014; 22(11): 2830-2836. doi: 10.1007/s00167-014-2852-5.
  3. Ottaviani S, Ayral X, Dougados M, gossec L. Pigmentedvillonodular synovitis: A retrospective single- center study of 122cases and review of the literature. Semin Arthritis Rheum 2011;40(6): 546-539. doi: 10.1016/j.semarthrit.2010.07.005.
  4. Lavrador JP, Oliveira E, gil N, Francisco AF, Livraghi S. C1-C2 pigmented villonodular synovitis and clear cell carcinoma: Unexpected presentation of a rare disease and a review of theliterature. Eur Spine J 2015; 24 (Suppl 4): S465-S471. doi: 10.1007/s00586-014-3396-6.
  5. Myers BW, Masi AT, Feigenbaum SL. Pigmented villo- nodular synovitis and tenosynovitis: A clinical epidemiologicstudy of 166 cases and literature review. Medicine 1980; 59(3): 223-238. PMID:7412554
  6. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz g, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103(3): 690-695. DOI:10.1073/pnas.0507321103
  7. Nassar WA, BassionyAA, Elghazaly HA. Treatment of diffuse pigmented villonodular synovitis of the knee with combined surgical and radiosynovectomy. HSS J 2009; 5(1): 19-23. doi: 10.1007/s11420-008-9104-5
  8. Fiocco U, Sfriso P, Lunardi F, Pagnin E, Oliviero F, Scagliori E, et al. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis. Autoimmun Rev 2010; 9(11): 780-784. doi: 10.1016/j.autrev.2010.07.001.
  9. Kaneko K, Nakahara D, Tobe M, Iwase H, Inoue Y, Ohbayashi O, et al. Pigmented villonodular synovitis of the ankle in an adolescent. Int Orthop 2000; 24(4): 234- 237. DOI:10.1007/s002640000141
  10. Park g, Kim YS, Kim JH, Lee SW, Song SY, Choi EK, et al. Low-dose external beam radiotherapy as a postoperative treatment for patients with diffuse pigmented villonodular synovitis of the knee: 4 recurrences in 23
  11. Wiss DA. Recurrent villonodular synovitis of the knee. patients followed for mean 9 years. Acta Orthop 2012; 83(3): 256-260. doi: 10.3109/17453674.2012.678803.
  12. Snoots WM, Watkins D, Dockery D, Mennel R, Cheek BS. Pigmented villonodular synovitis responsive to imatinib therapy. Proc 2011; 24(2): 134-138. doi: 10.1080/08998280.2011.11928700.
  13. Ray RA, Morton CC, Lipinski KK, Corson JM, Fletcher JA. Cytogenetic evidence of clonality in a case of pigmented villonodular synovitis. Cancer 1991; 67(1):121125.DOI:10.1002/10970142(19910101)67:1<1 21::aidcncr2820670122>3.0.co;2-p
  14. Chen WM, Wu PK, Liu CL. Simultaneous anterior and posterior synovectomies for treating diffuse pigmented villonodular synovitis. Clin Orthop Relat Res 2012; 470(6): 1755-1762. doi: 10.1007/s11999-012-2288-5
  15. Nakahara H, Matsuda S, Harimaya K, Sakamoto A, Matsumoto Y, Okazaki K, Tashiro Y, Iwamoto Y. Clinical results of open synovectomy for treatment of diffuse pigmented villonodular synovitis of the knee: Case series and review of literature. Knee 2012; 19(5): 684-687. DOI: 10.1016/j.knee.2011.12.002
  16. Nishida Y, Tsukushi S, Nakashima H, Sugiura H, Yamada Y, Urakawa H, et al. Osteochondral destruction in pigmented villonodular synovitis during the clinical course. J Rheumatol 2012; 39(2): 345-351. doi: 10.3899/ jrheum.110730.
  17. Liu XY, Yang YF, Wu CT, Xiao FJ, Zhang QW, Ma XN, et al. Spred2 is involved in imatinib induced cytotoxicity in chronic myeloid leukemia cells. Biochem Biophys Res Commun 2010; 393(4): 637-642. doi: 10.1016/j. bbrc.2010.02.044.
  18. Cassier PA, gelderblom H, Stacchiotti S, Thomas D, Maki Rg, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012; 118(6): 1649-1655. doi: 10.1002/ cncr.26409
  19. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol 2011; 23(4): 361-366. doi: 10.1097/CCO.0b013e328347e1e3.
  20. Stacchiotti S, Crippa F, Messina A, Pilotti S, gronchi A, Blay JY, et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res 2013; 3(1): 8.  doi: 10.1186/2045-3329-3-8.
  21. Xie G, Jiang N, Liang C, Zeng J, Chen Z, Xu Q, et al. Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases. PLoS One 2015; 10(3) :e0121451. doi: 10.1371/journal.pone.0121451.
  22. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A,Gambarotti M, et al. Tenosynovial giant cell tumour/ pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer Oxf Engl 2015; 51(2):210–7. doi: 10.1016/j.ejca.2014.11.001
  23. Successful treatment with yttrium-90. Clin Orthop 1982; 169:139–44. PMID:7105568
  24. Shabat S, Kollender Y,Merimsky O, Isakov J, Flusser G, NyskaM, et al. The use of surgery and yttrium90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatol Oxf Engl 2002;           41(10):1113–8.         DOI:10.1093/ rheumatology/41.10.1113
  25. Bickels J, Isaakov J, Kollender Y, Meller I. Unacceptable complications following intra-articular injection of yttrium 90 in the ankle joint for diffuse pigmented villonodular synovitis. J Bone Joint Surg Am 2008; 90(2):326–8. doi: 10.2106/JBJS.G.00441
  26. Ravi V, Wang W, Araujo DM, Ludwig JA. Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. In: ASCO Annual Meeting; 2010; Chicago, Illinois. J Clin Oncol 2010; 28:15s (suppl; abstr 10011).
  27. Kurtz J.E, Asmane I, Voegeli A.C, Neuville A, Dufresne A, Litique V, et al. A V530IMutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis. Sarcoma 2010, 4. DOI; 10.1155/2010/458156
  28. Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.Br J Cancer 2010; 10;103(4):482- 5. doi: 10.1038/sj.bjc.6605783
  29. Dao A, Benchakroun N, Jabir H, Taleb A, Bouchbika Z, Tawfiq N, et al. Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report. J Med Case Rep 2014; 9;8:416. doi: 10.1186/1752-1947-8-416
  30. Chen K, Ren Q, Han XR, Zhang XN, Wei B, Bai XZ. Imatinib mesylate induces mitochondria-dependent apoptosis and inhibits invasion of human pigmented villonodular synovitis fibroblast-like synovial cells. Oncol Rep 2016; 35(1):197-204. DOI; 10.3892/or.2015.4350
  31. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011; 23(4):361-6. doi: 10.1097/CCO.0b013e328347e1e3.
  32. Brahmi M, Vinceneux A, A. Cassie Ph. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis:Targeting the CSF1/CSF1R Axis. Curr. Treat. Options in Oncol 2016; 17(10). doi: 10.1007/s11864-015-0385-x.
  33. Verspoor FGM, Zee AAG, Hannink G, van der Geest ICM,Veth RPH, Schreuder HWB. Long-term follow-up results of primary and recurrent pigmented villonodular synovitis. Rheumatol Oxf Engl 2014; 53(11):2063–70. doi: 10.1093/rheumatology/keu230.